Loading…
Employees: 113
Size Aura Biosciences (AURA) is a United States Health Care company (Biotechnology) with a market value of $680M, the 2504th largest of 3,117 United States companies the cockpit tracks. Shares closed at $6.56 on 6 Nov 2026.
Performance Over six months the shares fell 21.9%, against -22.4% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 19 in its peer set.
Short interest Short interest is 10.5% of the free float (15 Oct 2026).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$1.15M | -$1.13M | -$1.22M | -$1.29M | -$1.18M |
| EBITDA | -$137M | -$112M | -$94.9M | -$83.7M | -$59.1M |
| Net income | -$131M | -$106M | -$86.9M | -$76.4M | -$58.8M |
| Free cash flow | -$103M | -$85.2M | -$81.1M | -$64.6M | -$55.7M |
| Capital expenditure | $344,000 | $447,000 | $1.25M | $709,000 | $1.09M |
| Total debt | $16.6M | $17.4M | $18.8M | $19.6M | $20.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AURA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.8% | -12.5% | 2nd highest of 21 |
| 6-month return | -21.9% | -22.4% | 9th highest of 19 |
| Distance from 52-week high | -31.2% | -46.6% | 4th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 4.7× | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | 3.9× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 2.1× | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 4.1× | 35.4% | +27.2% |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | 625.6× | n/a | n/a |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | 3.9× | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | 2.7× | -8.3% | -1.3% |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | 2.0× | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | 43.1× | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 1.6× | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | 20.3× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | 13.1× | 43.2% | +21.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | 8.2× | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 11.2× | 40.0% | +143.5% |